ArticleCureus2025
Differential Pregnancy Decisions in a Woman With a Recurrent Prenatal Diagnosis of Hypophosphatasia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypophosphatasia (HPP) is a rare inherited bone disorder caused by ALPL gene mutations, leading to reduced alkaline phosphatase (ALP) activity and impaired bone mineralization. Although its prevalence is relatively higher in Japan, prenatal diagnosis remains challenging. In particular, obstetricians and clinical geneticists, who are typically involved in prenatal assessment, often have limited experience with this condition due to its rarity. Among the various types of HPP, the prenatal benign form has a favorable prognosis, yet awareness and understanding of this specific subtype are limited. We report a case involving two separate pregnancies in the same woman, both diagnosed prenatally with HPP. During the second pregnancy, counseling was provided at 21 weeks by a physician. Given the rarity of HPP, even specialists such as obstetricians, pediatricians, or clinical geneticists often have limited direct clinical experience with the condition. Consequently, the counseling leaned toward a negative outlook, and the patient opted for termination. In contrast, during the third pregnancy, counseling began at nine weeks with detailed and balanced information, informed by the previous case and supported by a multidisciplinary team. This time, the patient elected to continue the pregnancy. The neonate was diagnosed with prenatal benign HPP and showed favorable clinical progress. This case highlights how the timing, quality, and balance of prenatal counseling can significantly influence parental decision-making in pregnancies complicated by rare diseases. In cases of rare conditions such as HPP, early and accurate counseling by an experienced multidisciplinary team is essential to support informed and autonomous decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.